Skip to content
OpenCapital
Get started

JBIO JBIO Cash & Equivalents

Cash & Equivalents at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$5.5B+17.5%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$78.36M+26.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$114.35M+108%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$75.08M-2.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$176.35M+51.7%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K—
Free cash flow-$33.7M—

Valuation

See full
Market cap$1.33B—
Enterprise value$1.28B—

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity0×—
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's cash & equivalents?
JBIO (JBIO) reported cash & equivalents of $55.09M in Q1 2026.
How has JBIO's cash & equivalents changed year-over-year?
JBIO's cash & equivalents increased by 24.6% year-over-year, from $44.22M to $55.09M.
What is the long-term trend for JBIO's cash & equivalents?
Over 5 years (2020 to 2025), JBIO's cash & equivalents has grown at a 80.6% compound annual growth rate (CAGR), from $4.6M to $88.44M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.